Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compounded Pyrimethamine: 'Personalized Medicine' Or 'Unapproved Drug'?

Executive Summary

Responding to the Express Scripts' deal to promote use of a compounded alternative to its drug, Turing says physicians shouldn't prescribe the compound, since it is an unapproved and unsafe drug. But the compounder, Imprimis, says each prescription is custom-made, making it a "personalized medicine."

Advertisement

Related Content

Compounding For Lower Prices Not PBMs’ New ‘Game Plan,’ Lawmakers Told
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel